Sulphone induced exfoliative dermatitis and hepatitis

Area of Science:

• Dermatology
• Hepatology
• Pharmacology

Background:

• Dapsone is a key medication for leprosy treatment.
• Previous reports linked high dapsone doses (≥200 mg/day) to exfoliative dermatitis and hepatitis.
• The safety profile of lower dapsone doses in leprosy management requires further investigation.

Observation:

• A 40-year-old female patient initiated dapsone therapy at 100 mg/day for leprosy.
• Within six weeks, she developed severe exfoliative dermatitis and hepatitis.
• This adverse event occurred at a lower dapsone dosage than previously documented.

Findings:

• The patient's condition was successfully managed with corticosteroid administration.
• This suggests corticosteroids may be an effective treatment for dapsone-induced toxicity.
• The case highlights potential risks associated with even moderate dapsone dosages.

Implications:

• Clinicians should be vigilant for dapsone-induced exfoliative dermatitis and hepatitis, even at 100 mg/day.
• Corticosteroids represent a viable therapeutic option for managing these adverse reactions.
• Further research into dapsone's dose-dependent toxicity in leprosy patients is warranted.